202 related articles for article (PubMed ID: 26367730)
1. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Kan G; Dong W
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3063-71. PubMed ID: 26367730
[TBL] [Abstract][Full Text] [Related]
2. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Berretta M; Stanzione B; Di Francia R; Tirelli U
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4207-9. PubMed ID: 26636502
[No Abstract] [Full Text] [Related]
3. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Qing Y; Li Q; Ren T; Xia W; Peng Y; Liu GL; Luo H; Yang YX; Dai XY; Zhou SF; Wang D
Drug Des Devel Ther; 2015; 9():901-9. PubMed ID: 25733810
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Pei R; Zhang W; Wang S; Huang X; Zou Y
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115210
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
Mou H; Yang QA; Yu L; Wang T; Liu K; Shen R; Pan X; Dai Y; Wan Q; Zhou F; Qian L; Chen D; Yau T; Dong X; Wang X; Wang S
J Gastroenterol Hepatol; 2021 Sep; 36(9):2601-2609. PubMed ID: 33656759
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
7. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
11. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner.
Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D
Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337
[TBL] [Abstract][Full Text] [Related]
12. PD-L1
Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
[No Abstract] [Full Text] [Related]
13. Differential expression of APE1 in hepatocellular carcinoma and the effects on proliferation and apoptosis of cancer cells.
Sun Z; Zhu Y; Aminbuhe ; Fan Q; Peng J; Zhang N
Biosci Trends; 2018; 12(5):456-462. PubMed ID: 30473552
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.
Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
J Cancer Res Clin Oncol; 2006 Sep; 132(9):547-55. PubMed ID: 16763805
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
17. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis.
Di Maso V; Mediavilla MG; Vascotto C; Lupo F; Baccarani U; Avellini C; Tell G; Tiribelli C; Crocè LS
PLoS One; 2015; 10(12):e0143289. PubMed ID: 26624999
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
